Oral side effects of COVID‐19 vaccines in 32 European countries: Analysis of EudraVigilance reports

The recent reports of oral side effects (SEs) following COVID‐19 vaccination warrant further investigation into their prevalence, severity, and aetiology. This study was conducted to synthesize the first‐ever population‐level evidence about oral SEs of COVID‐19 vaccines in Europe. The European Union...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2023-05, Vol.95 (5), p.e28771-n/a
Main Authors: Riad, Abanoub, Schulz‐Weidner, Nelly, Dziedzic, Arkadiusz, Howaldt, Hans‐Peter, Attia, Sameh
Format: Article
Language:English
Subjects:
Adverse Drug Reaction Reporting Systems
Anaphylaxis
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
Drug-Related Side Effects and Adverse Reactions
Europe - epidemiology
Female
Females
Humans
Immunization
Male
oral manifestations
Pharmacovigilance
Population studies
Risk factors
Side effects
Taste
Vaccines
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3881-1af65d1c142e031c349f51d568b96fce99b3f5104c5db02a634a85e97734c1443
cites cdi_FETCH-LOGICAL-c3881-1af65d1c142e031c349f51d568b96fce99b3f5104c5db02a634a85e97734c1443
container_end_page n/a
container_issue 5
container_start_page e28771
container_title Journal of medical virology
container_volume 95
creator Riad, Abanoub
Schulz‐Weidner, Nelly
Dziedzic, Arkadiusz
Howaldt, Hans‐Peter
Attia, Sameh
description The recent reports of oral side effects (SEs) following COVID‐19 vaccination warrant further investigation into their prevalence, severity, and aetiology. This study was conducted to synthesize the first‐ever population‐level evidence about oral SEs of COVID‐19 vaccines in Europe. The European Union Drug Regulating Authorities Pharmacovigilance (EudraVigilance) database was accessed in August 2022 to extract summary data of all potential oral SEs reported after COVID‐19 vaccination. The data were reported descriptively and cross‐tabulated to facilitate sub‐group analysis per vaccine type, sex, and age group. Dysgeusia was the most commonly reported oral SE (0.381 case per each 100 received reports), followed by oral paraesthesia (0.315%), ageusia (0.296%), lip swelling (0.243%), dry mouth (0.215%), oral hypoaesthesia (0.210%), swollen tongue (0.207%), and taste disorder (0.173%). Females had significantly (Sig. 
doi_str_mv 10.1002/jmv.28771
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2817777111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2819544220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-1af65d1c142e031c349f51d568b96fce99b3f5104c5db02a634a85e97734c1443</originalsourceid><addsrcrecordid>eNp10MtKAzEUBuAgiq2XhS8gATe6GM1JMpe4K7VqRelGux3SzBlJmc7UpFPpzkfwGX0SY6suBLMJhO_85PyEHAE7B8b4xXS2POdZmsIW6QJTSaRYCtuky0AmUZJA3CF73k8ZY5nifJd0RMqBC5BdgiOnK-ptgRTLEs3C06ak_dF4ePXx9g6KLrUxtkZPbU0Fp4PWNXPUNTVNWy-cRX9Je7WuVt6uJwdt4fTYPttK1wapw3njFv6A7JS68nj4fe-Tp-vBY_82uh_dDPu9-8iILIMIdJnEBRiQHJkAI6QqYyjiJJuopDSo1ESEByZNXEwY14mQOotRpamQYUiKfXK6yZ275qVFv8hn1huswmewaX3OM0jDAYBAT_7QadO6sMlaqVhKzllQZxtlXOO9wzKfOzvTbpUDy7-6z0P3-br7YI-_E9vJDItf-VN2ABcb8GorXP2flN89jDeRnyDcjC8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2819544220</pqid></control><display><type>article</type><title>Oral side effects of COVID‐19 vaccines in 32 European countries: Analysis of EudraVigilance reports</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Riad, Abanoub ; Schulz‐Weidner, Nelly ; Dziedzic, Arkadiusz ; Howaldt, Hans‐Peter ; Attia, Sameh</creator><creatorcontrib>Riad, Abanoub ; Schulz‐Weidner, Nelly ; Dziedzic, Arkadiusz ; Howaldt, Hans‐Peter ; Attia, Sameh</creatorcontrib><description>The recent reports of oral side effects (SEs) following COVID‐19 vaccination warrant further investigation into their prevalence, severity, and aetiology. This study was conducted to synthesize the first‐ever population‐level evidence about oral SEs of COVID‐19 vaccines in Europe. The European Union Drug Regulating Authorities Pharmacovigilance (EudraVigilance) database was accessed in August 2022 to extract summary data of all potential oral SEs reported after COVID‐19 vaccination. The data were reported descriptively and cross‐tabulated to facilitate sub‐group analysis per vaccine type, sex, and age group. Dysgeusia was the most commonly reported oral SE (0.381 case per each 100 received reports), followed by oral paraesthesia (0.315%), ageusia (0.296%), lip swelling (0.243%), dry mouth (0.215%), oral hypoaesthesia (0.210%), swollen tongue (0.207%), and taste disorder (0.173%). Females had significantly (Sig. &lt; 0.001) a higher prevalence of all most common (top 20) oral SEs, except for salivary hypersecretion, which was equally prevalent among females and males. The present study revealed a low prevalence of oral SEs, with taste‐related, other sensory and anaphylactic SEs being the most common SEs in Europe, similar to what was found earlier among the US population. Future studies should explore the potential risk factors of oral sensory and anaphylactic SEs to verify whether they are causally linked to COVID‐19 vaccines.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.28771</identifier><identifier>PMID: 37212314</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adverse Drug Reaction Reporting Systems ; Anaphylaxis ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention &amp; control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; Drug-Related Side Effects and Adverse Reactions ; Europe - epidemiology ; Female ; Females ; Humans ; Immunization ; Male ; oral manifestations ; Pharmacovigilance ; Population studies ; Risk factors ; Side effects ; Taste ; Vaccines ; Virology</subject><ispartof>Journal of medical virology, 2023-05, Vol.95 (5), p.e28771-n/a</ispartof><rights>2023 The Authors. published by Wiley Periodicals LLC.</rights><rights>2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-1af65d1c142e031c349f51d568b96fce99b3f5104c5db02a634a85e97734c1443</citedby><cites>FETCH-LOGICAL-c3881-1af65d1c142e031c349f51d568b96fce99b3f5104c5db02a634a85e97734c1443</cites><orcidid>0000-0001-5918-8966</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37212314$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riad, Abanoub</creatorcontrib><creatorcontrib>Schulz‐Weidner, Nelly</creatorcontrib><creatorcontrib>Dziedzic, Arkadiusz</creatorcontrib><creatorcontrib>Howaldt, Hans‐Peter</creatorcontrib><creatorcontrib>Attia, Sameh</creatorcontrib><title>Oral side effects of COVID‐19 vaccines in 32 European countries: Analysis of EudraVigilance reports</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>The recent reports of oral side effects (SEs) following COVID‐19 vaccination warrant further investigation into their prevalence, severity, and aetiology. This study was conducted to synthesize the first‐ever population‐level evidence about oral SEs of COVID‐19 vaccines in Europe. The European Union Drug Regulating Authorities Pharmacovigilance (EudraVigilance) database was accessed in August 2022 to extract summary data of all potential oral SEs reported after COVID‐19 vaccination. The data were reported descriptively and cross‐tabulated to facilitate sub‐group analysis per vaccine type, sex, and age group. Dysgeusia was the most commonly reported oral SE (0.381 case per each 100 received reports), followed by oral paraesthesia (0.315%), ageusia (0.296%), lip swelling (0.243%), dry mouth (0.215%), oral hypoaesthesia (0.210%), swollen tongue (0.207%), and taste disorder (0.173%). Females had significantly (Sig. &lt; 0.001) a higher prevalence of all most common (top 20) oral SEs, except for salivary hypersecretion, which was equally prevalent among females and males. The present study revealed a low prevalence of oral SEs, with taste‐related, other sensory and anaphylactic SEs being the most common SEs in Europe, similar to what was found earlier among the US population. Future studies should explore the potential risk factors of oral sensory and anaphylactic SEs to verify whether they are causally linked to COVID‐19 vaccines.</description><subject>Adverse Drug Reaction Reporting Systems</subject><subject>Anaphylaxis</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention &amp; control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Europe - epidemiology</subject><subject>Female</subject><subject>Females</subject><subject>Humans</subject><subject>Immunization</subject><subject>Male</subject><subject>oral manifestations</subject><subject>Pharmacovigilance</subject><subject>Population studies</subject><subject>Risk factors</subject><subject>Side effects</subject><subject>Taste</subject><subject>Vaccines</subject><subject>Virology</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp10MtKAzEUBuAgiq2XhS8gATe6GM1JMpe4K7VqRelGux3SzBlJmc7UpFPpzkfwGX0SY6suBLMJhO_85PyEHAE7B8b4xXS2POdZmsIW6QJTSaRYCtuky0AmUZJA3CF73k8ZY5nifJd0RMqBC5BdgiOnK-ptgRTLEs3C06ak_dF4ePXx9g6KLrUxtkZPbU0Fp4PWNXPUNTVNWy-cRX9Je7WuVt6uJwdt4fTYPttK1wapw3njFv6A7JS68nj4fe-Tp-vBY_82uh_dDPu9-8iILIMIdJnEBRiQHJkAI6QqYyjiJJuopDSo1ESEByZNXEwY14mQOotRpamQYUiKfXK6yZ275qVFv8hn1huswmewaX3OM0jDAYBAT_7QadO6sMlaqVhKzllQZxtlXOO9wzKfOzvTbpUDy7-6z0P3-br7YI-_E9vJDItf-VN2ABcb8GorXP2flN89jDeRnyDcjC8</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Riad, Abanoub</creator><creator>Schulz‐Weidner, Nelly</creator><creator>Dziedzic, Arkadiusz</creator><creator>Howaldt, Hans‐Peter</creator><creator>Attia, Sameh</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5918-8966</orcidid></search><sort><creationdate>202305</creationdate><title>Oral side effects of COVID‐19 vaccines in 32 European countries: Analysis of EudraVigilance reports</title><author>Riad, Abanoub ; Schulz‐Weidner, Nelly ; Dziedzic, Arkadiusz ; Howaldt, Hans‐Peter ; Attia, Sameh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-1af65d1c142e031c349f51d568b96fce99b3f5104c5db02a634a85e97734c1443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adverse Drug Reaction Reporting Systems</topic><topic>Anaphylaxis</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention &amp; control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Europe - epidemiology</topic><topic>Female</topic><topic>Females</topic><topic>Humans</topic><topic>Immunization</topic><topic>Male</topic><topic>oral manifestations</topic><topic>Pharmacovigilance</topic><topic>Population studies</topic><topic>Risk factors</topic><topic>Side effects</topic><topic>Taste</topic><topic>Vaccines</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Riad, Abanoub</creatorcontrib><creatorcontrib>Schulz‐Weidner, Nelly</creatorcontrib><creatorcontrib>Dziedzic, Arkadiusz</creatorcontrib><creatorcontrib>Howaldt, Hans‐Peter</creatorcontrib><creatorcontrib>Attia, Sameh</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riad, Abanoub</au><au>Schulz‐Weidner, Nelly</au><au>Dziedzic, Arkadiusz</au><au>Howaldt, Hans‐Peter</au><au>Attia, Sameh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral side effects of COVID‐19 vaccines in 32 European countries: Analysis of EudraVigilance reports</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2023-05</date><risdate>2023</risdate><volume>95</volume><issue>5</issue><spage>e28771</spage><epage>n/a</epage><pages>e28771-n/a</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>The recent reports of oral side effects (SEs) following COVID‐19 vaccination warrant further investigation into their prevalence, severity, and aetiology. This study was conducted to synthesize the first‐ever population‐level evidence about oral SEs of COVID‐19 vaccines in Europe. The European Union Drug Regulating Authorities Pharmacovigilance (EudraVigilance) database was accessed in August 2022 to extract summary data of all potential oral SEs reported after COVID‐19 vaccination. The data were reported descriptively and cross‐tabulated to facilitate sub‐group analysis per vaccine type, sex, and age group. Dysgeusia was the most commonly reported oral SE (0.381 case per each 100 received reports), followed by oral paraesthesia (0.315%), ageusia (0.296%), lip swelling (0.243%), dry mouth (0.215%), oral hypoaesthesia (0.210%), swollen tongue (0.207%), and taste disorder (0.173%). Females had significantly (Sig. &lt; 0.001) a higher prevalence of all most common (top 20) oral SEs, except for salivary hypersecretion, which was equally prevalent among females and males. The present study revealed a low prevalence of oral SEs, with taste‐related, other sensory and anaphylactic SEs being the most common SEs in Europe, similar to what was found earlier among the US population. Future studies should explore the potential risk factors of oral sensory and anaphylactic SEs to verify whether they are causally linked to COVID‐19 vaccines.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37212314</pmid><doi>10.1002/jmv.28771</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0001-5918-8966</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0146-6615
ispartof Journal of medical virology, 2023-05, Vol.95 (5), p.e28771-n/a
issn 0146-6615
1096-9071
language eng
recordid cdi_proquest_miscellaneous_2817777111
source Wiley-Blackwell Read & Publish Collection
subjects Adverse Drug Reaction Reporting Systems
Anaphylaxis
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
Drug-Related Side Effects and Adverse Reactions
Europe - epidemiology
Female
Females
Humans
Immunization
Male
oral manifestations
Pharmacovigilance
Population studies
Risk factors
Side effects
Taste
Vaccines
Virology
title Oral side effects of COVID‐19 vaccines in 32 European countries: Analysis of EudraVigilance reports
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A05%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20side%20effects%20of%20COVID%E2%80%9019%20vaccines%20in%2032%20European%20countries:%20Analysis%20of%20EudraVigilance%20reports&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Riad,%20Abanoub&rft.date=2023-05&rft.volume=95&rft.issue=5&rft.spage=e28771&rft.epage=n/a&rft.pages=e28771-n/a&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.28771&rft_dat=%3Cproquest_cross%3E2819544220%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3881-1af65d1c142e031c349f51d568b96fce99b3f5104c5db02a634a85e97734c1443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2819544220&rft_id=info:pmid/37212314&rfr_iscdi=true